l Introduction
Ritodrine hydrochloride is a beta-sympathomimetic drug, with predominantly beta 2-effects, which is effective in the treatment of premature labor [6] . The compound may be administered intravenously, intramusculary or orally. It is inactivated by glucuronide and sulphate conjugation and excreted in the urine. The placental transfer of ritodrine was initially suspected on clinical grounds, namely the increase in fetal heart rate associated with ritodrine infusion [1] . Using radioactively labelled drug, KLEIN -HOUT and VETH [5] demonstrated placental transfer in the sheep. In this model, fetal blood levels of radioactivity never exceeded 20% of those present in the ewe. These results are in accordance with similar investigations undertaken by COSMI [2] . However, data from studies using radiolabelled drug give no indication of the ratio between unaltered ritodrine and its conjugates. WEIDINGER [8] and WIEST [9] published results of diaplacental passage, using tritium-tagged fenoterol in legal abortions. The development of radioimmunoassay for ritodrine [3, 7] permitted measurement of active drug without the inactive conjugates. In a study using the radioimmunoassay technique in pregnant women, GANDAR et al. [3] confirmed the placental transfer of ritodrine itself in humans. The present study reports data on ritodrine concentrations in maternal and fetal serum and amniotic fluid, measured by radio-immunoassay. Samples were taken from eight patients undergoing elective cesarian section following intravenous infusion of ritodrine.
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Materials and methods
l Radioimmunoassay of ritodrine
Unlabelled ritodrine hydrochloride of pharmaceutical grade, tritiumlabelled ritodrine hydrochloride and anti-ritodrine serum were supplied by DUPHAR B. V., Weesp, The Netherlands. 0300-5577/82/0010-0119S02.00
The anti-ritodrine antiserum was tested for immunological cross reactions with: Isoxsuprine, fenoterol, salbutamol, terbutaline, hLH, hFSH, hCG, hCGa, hCG/3 and relaxin. The only crossreaction was with fenoterol, but even this was slight and not significant. Progesterone, 17/J-estradiol, adrenalin, noradrenalin, albumin and prostaglandins E 2 and F 2 a showed no interference with the assay procedure, details of which are pubÜshed elsewhere [7] .
Volunteers
Eight healthy, pregnant, women between 37 and 41 weeks of gestation and not in labor, who were to undergo elective cesarian section, agreed to participate after being fully informed on the aim of the study and the possible effects of ritodrine infusion. The indications for cesarian section were: Iterative (n = 4), pathological pelvis (n = 3) and a breech presentation (n = 1). The clinical, hormonal and echographical investigations gave no abnormal results or contra-indication to the administration ofbeta-mimetics.
Procedure
The patients were placed in the left lateral position and ritodrine infusion was started (Fig. 1) . The infusion was controlled by means of a drop-by-drop regulation pump. The dose was 2 g · kg"
1 · min" peripheral vein for ritodrine assay. Surgical procedures started with patients in the half left lateral decubitus position. After anesthesia was established, the following procedures were carried out in rapid succession: ritodrine infusion stopped, peripheral blood sampling, laparotomy, uterine vein blood sampling, amniotic fluid sampling by amniocentesis, hysterotomy, fetal extraction, umbilical artery and vein blood sampling, child placed under pediatric care. All cesarian sections were performed by the same operator. One and four hours after anesthesia was established, maternal blood samples were drawn for ritodrine assay.
Results
Newborns
Tab. I shows the data for the newborn babies. All the children's weights feil within the 10° to 90°p ercentiles for gestational age. One baby had a one minute APGAR score less than 7 and another acidosis (pH < 7.15) related to maternal "hypoxichypercapnic" Status during tracheal intubation. The course during the neonatal period was normal for all babies. Fig. 2 shows the development of the maternal ritodrine levels during the infusion and after its discontinuation. Tab. II shows simultaneous ritodrine concentrations in the maternal compartment (peripheral and uterine veins) and the fetal compartment (umbilical artery and vein, amniotic fluid) at the moment of cesarian section, i.e., after 2 hours infusion. 
Ritodrine concentrations
Discussion
Our results, with respect to peripheral maternal blood, appear to agree with those of other authors. GANDAR et al. [3] infused six non-pregnant women with 150 Mg · min" 1 for 60 minutes and obtained serum ritodrine concentrations of 28.9 ± 2.5 ng/ml (mean ± SEM) at 20 minutes and 41.0 ± l .9 ng/ml at 50 minutes.
Tab. II. Concentrations of ritodrine (ng/ml) in maternal and fetal compartments at the time of cesarian section. Comparison of concentrations, after 2 hours infusion, between the peripheral venous blood and uterine venous blood, showed a significant difference (p < 0.02, paired-t test). The mean concentrations were, respectively 54.2 ±11.8 ng/ml and 37.5 ± 10.3 ng/ml. This difference probably reflects the trans-placental passage.
In the fetal circulation, ritodrine levels in blood from the umbilical vein and artery did not differ significantly. The respective mean concentrations were 16.6 ± 8.9 ng/ml and 15.8 ± 4.8 ng/ml. The mean ratio of fetal vein and peripheral maternal vein serum ritodrine concentrations was 0.30 ± 0.13 (mean ± SD). This is at variance with the results from GANPAR et al. [3] who found a mean ratio of 0.64 ± 0.25 (mean ± SD). However, comparison of results is hampered by the lack of standardization in the latter study. INGEMARS-SON et al. [4] studied the concentrations of terbutaline in plasma after bolüs intravenous administration of 250 g during the second stage of labor. The found of mean ratio for mixed cord blood: Maternal vein blood of 0.36 ±0.15 (mean ± SD). Finally, the similarity between mean concentrations in amniotic fluid (15.2 ± 8.7 ng/ml) 3 umbilical arterial blood (15.8 ± 4.8 ng/ml) and umbilical venous blood (16.6 ± 8.9 ng/ml) is striking. In äs far äs the ritodrine in the amniotic fluid originales in the fetal urine, these results suggest that the fetus does not conjugate this drug.
Summary
Ritodrine hydrochloride concentrations were measured by radioimmunoassay in maternal and fetal sera and amniotic fluid from eight, pregnant, volunteers. Each patient agreed to have 420 Mg · kg" 1 of ritodrine infused intra-venously over two hours prior to elective cesarian section. During infusion a blood sample was taken every 30 minutes from a maternal peripheral vein. Once anasthesia was established the infusion was discontinued. During surgery, samples were drawn from maternal peripheral vein, uterine vein, umbilical artery and vein, and amniotic fluid. All the children delivered were healthy and had a normal course during the neonatal period. Ritodrine concentrations in maternal and fetal compartments at the time of cesarian section were 54.2 ± 11.8 ng/ml (mean ± S.D.) in maternal peripheral vein, 37.5 ± 10.3 ng/ml in uterine vein, 15.8 ± 4.8 ng/ml in umbilical artery, 16.6 ± 8.9 ng/ml in umbilical vein, and 15.2 ± 8.7 ng/ml in amniotic fluid. There was a statistically significant difference (p < 0.02, paired-t test) between the mean ritodrine concentrations in sera from the maternal peripheral vein and uterine vein. This difference probably reflects transplacental passsage. The mean ratio of fetal vein and peripheral maternal vein serum ritodrine concentrations was 0.30 ± 0.13 (mean ± SD). The similarity between mean ritodrine concentrations in amniotic fluid, and sera from umbilical arterial and venous blood was striking. These results suggest that the fetus does not conjugate the drug. Les concentration de ritodrine dans les compartiments maternel et foetal au moment de la cesarienne etaient les suivantes: 54,2 ± 11,8 ng/ml (moyenne ± D.S.) dans la veine peripherique maternelle, 37,5 ± 10,3 ng/ml dans la veine uterine, 15,8 ± 4,8 ng/ml dans Tattere ombilicale, 16,6 ± 8,9 ng/ml dans k veine ombilicale, et 15,2 ± 8,7 ng/ml dans le liquide amniotique. H existe une difference statistiquement significative (p < 0,02) entre la concentration moyenne de ritodrine dans la veine peripherique et dans la veine uterine. Cette difference reflete probablement le passage transplacentaire. Le rapport moyen veine ombilicale/veine peripherique maternelle dans la concentration de ritodrine est de 0,30 ± 0,13 (moyenne ± D.S.). La süniütude entre les concentrations de ritodrine dans le liquide amniotique, Tariere ombilicale et la veine ombilicale est etonnante. Ces resultats suggerent que le foetus ne conjugue pas la substance.
